Oppenheimer has upgraded Procept Biorobotics Corp (PRCT) to Outperform from Perform as of September 1, 2025. The stock is currently priced at $29.16.
This upgrade reflects a more optimistic outlook on the company’s prospects, potentially indicating improved fundamentals or enhanced confidence in its strategic direction. Procept Biorobotics is a commercial-stage surgical robotics firm based in San Jose, California, focusing on transformative solutions in urology. It develops the AQUABEAM Robotic System, which utilizes advanced imaging and robotics to perform minimally invasive surgeries for benign prostatic hyperplasia (BPH).
As of November 20, 2025, Procept Biorobotics has a market capitalization of $1.6 billion and a trailing twelve-month EPS of -1.54. The company is set to report its next earnings on August 4, 2026, with an estimated EPS of -0.29 and revenue of $104.8 million. Recent earnings performance has shown surprises, including a Q3 2025 EPS of -0.38 against an estimate of -0.42.
Analyst consensus as of November 1, 2025, includes 7 Strong Buy, 9 Buy, and 3 Hold ratings, indicating a general positive sentiment among analysts. The recent upgrade from Oppenheimer underscores the evolving perception of Procept Biorobotics in the market.
Analyst ratings are based on research and financial models and should be considered alongside company fundamentals and market conditions.